Loading...
•
Dec 31, 2025
Rezolute Inc Q2 2026 Earnings Report
Rezolute reported higher operating expenses in the second quarter of fiscal 2026, resulting in a wider net loss year-over-year.
Key Takeaways
For Q2 fiscal 2026, Rezolute reported a net loss of 22774000 compared to 15730000 in the prior year period, driven by increased R&D and G&A expenses. Total operating expenses rose to 24221000 for the quarter.
Net loss was 22774000 compared to 15730000 in Q2 fiscal 2025.
R&D expenses increased to 14348000 from 12627000 year-over-year.
G&A expenses increased to 9873000 from 4453000 year-over-year.
Cash, cash equivalents and marketable securities totaled 132938000 at December 31, 2025.
Forward Guidance
Rezolute continues advancing ersodetug for congenital and tumor hyperinsulinism and plans to meet with the FDA in Q1 2026 under Breakthrough Therapy Designation to determine next steps.
Positive Outlook
- Breakthrough Therapy Designation for ersodetug.
- All 59 participants who completed sunRIZE entered the open-label extension.
- 75% of EAP tumor HI patients discontinued IV dextrose/TPN.
- Topline data from upLIFT expected in the second half of 2026.
- Cash runway supported by 132938000 in cash and investments.
Challenges Ahead
- sunRIZE study did not meet primary or key secondary endpoints.
- Net loss widened year-over-year.
- Higher operating expenses driven by clinical trial activity.
- Reduction in force in December 2025.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...